Despite major advances in our understanding of breast cancer biology and the advent of novel diagnostic tools to predict survival and treatment response of breast cancer patients (i.e., MIB-1, IGkG, genetic tests, etc.)[1–3], time-honored tumor grading has been confirmed as one of the most reliable prognostic and predictive markers [4]. This evidence concerns the gene MIB1 and breast carcinoma.